Please enable Javascript
GI Oncology Now Conference Coverage
ASCO GI Symposium 2024
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
ASCO GI Symposium 2024: Focus on Liver Cancer
Coverage of the 2024 ASCO GI Symposium, focusing on liver cancer
International Society of Gastrointestinal Oncology 2023 Annual Meeting
GI Oncology Now reviews education from ISGIO 2023, featuring the latest advances in the field of GI cancer research.
Symposium on Clinical Interventional Oncology 2023
GI Oncology Now reviews practice-enhancing education from CIO 2023, featuring multidisciplinary specialties in oncology.
Advertisement
The Latest From GI Oncology Now
Investigating Absorbed Dose Response in 177Lu-DOTATATE for GEP-NETs
Katy Marshall
GEP-NETs
|
May 15, 2024
Researchers can quantify absorbed doses through serial postinfusion scintigraphy measurements of the γ-emissions.
Feasibility of Personalized Neoantigen Vaccines Plus Pembrolizumab for Advanced HCC
Mark Yarchoan, MD
Unresectable HCC
|
May 15, 2024
Dr. Yarchoan details neoantigen-specific T cell responses assessed in the study.
Modified Gustave Roussey Immune Score Detects ICI Response in BTC
Emily Menendez
Bile Duct Cancer
|
May 14, 2024
Determining which patients can benefit the most from immunotherapy remains elusive.
Effects of PD-1 Inhibitors on Real-world Treatment Patterns, Outcomes in Advanced HCC
Katy Marshall
Unresectable HCC
|
May 13, 2024
Researchers used descriptive statistics to analyze first-line treatment patterns.
Platinum Chemotherapy, PARP Inhibitors for Gastric or Esophageal Cancers
Nilay Sethi, MD, PhD
Gastric Cancer
|
May 13, 2024
Dr. Sethi continues his comments on NER deficiency in gastric cancer cell lines in response to cisplatin treatment.
Identifying HR and NER Deficiencies in Gastric Cancer for Targeted Treatment Strategies
Nilay Sethi, MD, PhD
Gastric Cancer
|
May 13, 2024
Dr. Sethi discusses homologous recombination and nucleotide excision repair pathways in DNA repair for cancers.
Effects of Anti–PD-1 Therapy on Long-term Outcomes in dMMR, MSI-H Rectal Cancer
Katy Marshall
Colorectal Cancer
|
May 10, 2024
Researchers noted that neoadjuvant anti–PD-1 treatment may serve as a curative-intent therapy.
Managing Defective Mismatch Repair in Gastroesophageal Adenocarcinoma
Matthew Strickland, MD
Gastroesophageal Cancer
|
May 8, 2024
Matthew Strickland, MD, discusses the current management of defective mismatch repair in gastroesophageal adenocarcinoma.
View More
Advertisement
Advertisement
Advertisement